Alnylam Pharmaceuticals | ALNY - Ativo Circulante





Ativo Circulante Alterar Data
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Arrowhead Research USD 1.84B 665.36M 2026-03
BioCryst Pharmaceuticals USD 373.62M 30.72M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Incyte USD 5.48B 460.36M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Moderna USD 5.77B 774M 2026-03
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Novartis USD 30.46B 2.26B 2025-12
PTC Therapeutics USD 2.25B 19.94M 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 30.95B 8.99B 2025-12
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Takeda JPY 3.09T 25.94B 2026-03
Tectonic Therapeutic USD 239.89M 17.47M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03
Xencor USD 482.85M 116.97M 2026-03